<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>The article is looking into the issue of global equitable access to Covid-19 vaccines from the perspective of intellectual property rights, in particular patents. The discussed topics include instruments that could potentially facilitate access to patent protected health technologies (Covid-19 vaccines). Some of them are non-voluntary in nature, like the compulsory licenses in accordance with the TRIPS Agreement and others rely on the voluntary participation of the pharmaceutical industry, such as the C-TAP and the Medicines Patent Pool. The article also explores the controversial initiative regarding an “intellectual property waiver” proposed by a number of WTO members.</p>
</abstract>

The article is looking into the issue of global equitable access to Covid-19 vaccines from the perspective of intellectual property rights, in particular patents. The discussed topics include instruments that could potentially facilitate access to patent protected health technologies (Covid-19 vaccines). Some of them are non-voluntary in nature, like the compulsory licenses in accordance with the TRIPS Agreement and others rely on the voluntary participation of the pharmaceutical industry, such as the C-TAP and the Medicines Patent Pool. The article also explores the controversial initiative regarding an “intellectual property waiver” proposed by a number of WTO members.

Access to Covid-19 Vaccine: Patents vs. People?

PhD, Associate Professor, University of Sarajevo

International and Comparative Law Review

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Access to Covid-19 Vaccine: Patents vs. People?"}

The article is looking into the issue of global equitable access to Covid-19 vaccines from the perspective of intellectual property rights, in particular...

Access to Covid-19 Vaccine: Patents vs. People?

Publicado en línea: 19 ago 2021

Páginas: 43 - 78

DOI: https://doi.org/10.2478/iclr-2021-0002

Palabras clave
Covid-19, vaccine, intellectual property, patents, TRIPS Agreement, intellectual property waiver, compulsory licence, C-TAP, Medicines Patent Pool

© 2021 Iza Razija Mešević, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Access to Covid-19 Vaccine: Patents vs. People?

Publicado en línea: 19 ago 2021

Páginas: 43 - 78

DOI: https://doi.org/10.2478/iclr-2021-0002

Palabras claveCovid-19, vaccine, intellectual property, patents, TRIPS Agreement, intellectual property waiver, compulsory licence, C-TAP, Medicines Patent Pool

© 2021 Iza Razija Mešević, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Palabras clave
Covid-19, vaccine, intellectual property, patents, TRIPS Agreement, intellectual property waiver, compulsory licence, C-TAP, Medicines Patent Pool